AaronSKesselheimMD

Hospital Medicine/Hospitalist

Assistant Professor of Medicine, Brigham and Women's Hospital

Dr. Kesselheim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

25 citations
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
Kerstin N Vokinger, Aaron S Kesselheim, Camille E G Glaus, Thomas J Hwang
JAMA Health Forum. 2022-08-05
9 citations
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
Ian T T Liu, Aaron S Kesselheim, Edward R Scheffer Cliff
JAMA. 2024-05-07
54 citations
Incentives for drug development--the curious case of colchicine.
Aaron S. Kesselheim, Daniel H. Solomon
The New England Journal of Medicine. 2010-06-03

Journal Articles

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Aaron Kesselheim, MD, JAMA Internal Medicine
Substitution of Generic Drugs and Biosimilars—Reply
Aaron Kesselheim, MD, JAMA Internal Medicine
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions
Aaron Kesselheim, MD, JAMA Internal Medicine
Drug Prices, Rebates, and Discounts
William B Feldman, Aaron S Kesselheim, JAMA
Missed Opportunities on Emergency Remdesivir Use
Aaron Kesselheim, MD, JAMA
False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications
Steven Woloshin, Aaron S Kesselheim, The New England Journal of Medicine
Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies
Mike Z Zhai, Carolyn T Lye, Aaron S Kesselheim, JAMA Internal Medicine
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act
Florence T Bourgeois, Aaron S Kesselheim, JAMA
Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012
Aaron S Kesselheim, Michael S Sinha, JAMA
Medicare Spending on Brand-Name Combination Medications vs Their Generic Constituents
Aaron Kesselheim, MD, JAMA
Feature Patent Term Restoration for Top-Selling Drugs in the USA
Aaron Kesselheim, MD, ScienceDirect
Join now to see all

Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAugust 2020
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAugust 2020
Drug Prices, Rebates, and DiscountsJuly 2020
US Spending Associated with Transition from Daily to 3-Times-Weekly Glatiramer AcetateJuly 2020
US Spending Associated with Transition from Daily to 3-Times-Weekly Glatiramer AcetateJuly 2020
Prices of Generic Drugs Associated with Numbers of ManufacturersDecember 2017
Prices of Generic Drugs Associated with Numbers of ManufacturersDecember 2017
Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United StatesNovember 2017
Join now to see all

FDA Urged to Levy Fines for Delayed Confirmatory Trials in Oncology and BeyondOctober 30th, 2024
Fewer Cancer Drugs Exempt from Pediatric Testing After RACE ActSeptember 18th, 2024
Do Neurology Patient Advocacy Groups Wield Too Much Power?August 26th, 2024
Join now to see all

Off-Label Prescribing: Comparative Evidence, Regulation, And UtilizationAgency For Healthcare Research And Quality2009–2011